NSAID-Induced Giant Gastric Ulcer Complicated by Massive Gastrocolic Fistula: A Case Report and Comprehensive Review of Contemporary Management Strategies

NSAID-Induced Giant Gastric Ulcer Complicated by Massive Gastrocolic Fistula: A Case Report and Comprehensive Review of Contemporary Management Strategies | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article NSAID-Induced Giant Gastric Ulcer Complicated by Massive Gastrocolic Fistula: A Case Report and Comprehensive Review of Contemporary Management Strategies Faizan Sheraz This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8206892/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract Background Gastrocolic fistula (GCF) represents a rare but life-threatening complication of peptic ulcer disease, with evolving etiology from predominantly benign to malignant causes over recent decades. NSAID-induced gastrocolic fistulas, while uncommon, pose significant diagnostic and therapeutic challenges in contemporary practice. Case Presentation: We present a 70-year-old female with chronic pain syndrome who developed a massive (4.5 cm) gastrocolic fistula secondary to chronic high-dose NSAID overuse (aspirin 3000 mg/day and ibuprofen 1000 mg/day for > 2 years). Clinical presentation included severe iron-deficiency anemia (hemoglobin 6.0 g/dL), melena, and constitutional symptoms. Comprehensive evaluation confirmed benign etiology through endoscopic visualization, histopathological examination, and cross-sectional imaging. Management and Outcomes: The patient underwent successful robotic-assisted laparoscopic surgery including distal gastrectomy, right hemicolectomy, and Roux-en-Y reconstruction. Postoperative course was uncomplicated with complete symptom resolution and excellent functional outcomes at 12-month follow-up. Literature Review: Systematic analysis of 127 published cases (2000–2024) reveals evolving epidemiology, diagnostic approaches, and treatment modalities for gastrocolic fistula. Contemporary management emphasizes multidisciplinary evaluation, advanced imaging techniques, and minimally invasive surgical approaches when feasible. Conclusions This case demonstrates successful management of a rare NSAID-induced complication using modern surgical techniques. The comprehensive literature review provides evidence-based recommendations for diagnosis, treatment selection, and prevention strategies in the contemporary management of gastrocolic fistula. Gastroenterology & Hepatology Gastrocolic fistula NSAID gastropathy peptic ulcer complications robotic surgery minimally invasive surgery literature review systematic analysis Figures Figure 1 Figure 2 Introduction Gastrocolic fistula (GCF) represents one of the most challenging complications in gastroenterology, characterized by abnormal communication between the stomach and colon with significant associated morbidity and mortality [1]. The condition has undergone a remarkable epidemiological transformation over the past four decades, shifting from predominantly benign peptic ulcer disease etiology to malignancy-associated causes in contemporary practice [2,3]. The historical context of gastrocolic fistula provides important insights into current management paradigms. In the pre-H2 receptor antagonist era (before 1970s), benign peptic ulcer disease accounted for 90% of gastrocolic fistulas, with NSAID-induced ulceration being a primary mechanism [4]. However, the introduction of effective acid suppression therapy, widespread Helicobacter pylori eradication programs, and improved understanding of peptic ulcer pathophysiology have dramatically reduced the incidence of ulcer-related complications [5,6]. Paradoxically, while overall peptic ulcer complications have declined, NSAID-induced gastrocolic fistula remains clinically relevant due to several contemporary factors: increasing NSAID utilization for cardiovascular prophylaxis in aging populations, widespread use for chronic pain management, and the emergence of combination therapy regimens [7,8]. The annual incidence of serious NSAID-related gastrointestinal complications, including perforation and fistula formation, ranges from 0.1-0.4% among chronic users, with significantly higher rates in high-risk populations [9,10]. This case report presents a rare example of massive NSAID-induced gastrocolic fistula successfully managed with robotic-assisted minimally invasive surgery, accompanied by a comprehensive review of contemporary literature examining epidemiology, pathophysiology, diagnostic approaches, and treatment modalities for this challenging condition. Case Presentation Patient Demographics and Presentation A 70-year-old Caucasian female presented to the emergency department with a 3-week history of progressive melena, generalized abdominal pain, profound fatigue, and 15-pound unintentional weight loss. The patient reported increasing weakness that significantly limited her activities of daily living and episodes of near-syncope with minimal exertion. Medical History and Risk Factors Past Medical History: Chronic lumbar spinal stenosis with chronic pain syndrome (15-year duration) Type 2 diabetes mellitus (HbA1c 7.1%, well-controlled on metformin) Essential hypertension (controlled on ACE inhibitor therapy) Osteoarthritis affecting bilateral knees and hands Gastroesophageal reflux disease with intermittent proton pump inhibitor use No prior history of peptic ulcer disease or gastrointestinal bleeding No family history of gastrointestinal malignancies or inflammatory bowel disease Medication History - Critical NSAID Exposure: Aspirin 500 mg six times daily (total: 3000 mg/day) for 2+ years Ibuprofen 200 mg five times daily (total: 1000 mg/day) for 3+ years Acetaminophen 1000 mg twice daily Intermittent omeprazole 20 mg daily (patient-initiated, inconsistent use) Metformin 1000 mg twice daily Lisinopril 10 mg daily Social History: Non-smoker, minimal alcohol consumption (1-2 drinks weekly), retired teacher, independent living situation. Physical Examination Vital Signs: Temperature 98.6°F, BP 110/65 mmHg (baseline 130-140/80-85), HR 105 bpm, RR 18/min, O2 sat 98% RA, BMI 24.2 kg/m² Physical Findings: General: Pale, chronically ill-appearing female in no acute distress HEENT: Marked conjunctival pallor, anicteric sclerae, dry mucous membranes Cardiovascular: Tachycardic regular rhythm, no murmurs or gallops Pulmonary: Clear to auscultation bilaterally Abdominal: Soft, diffusely tender with mild epigastric tenderness, no rebound or guarding, no palpable masses, normal bowel sounds Rectal: Melenic stool, no masses palpated Extremities: No edema, pale nail beds, normal pulses Laboratory Investigations Hematological Studies: Hemoglobin: 6.0 g/dL (normal: 12.0-15.5 g/dL) Hematocrit: 18.2% (normal: 36.0-46.0%) MCV: 72 fL (microcytic anemia) WBC: 8,500/μL, Platelets: 485,000/μL (reactive thrombocytosis) Iron Studies (confirming iron deficiency): Serum iron: 35 μg/dL (normal: 60-170 μg/dL) TIBC: 450 μg/dL (normal: 250-400 μg/dL) Transferrin saturation: 8% (normal: 20-50%) Ferritin: 8 ng/mL (normal: 15-150 ng/mL) Comprehensive Metabolic Panel: BUN: 35 mg/dL (mildly elevated), Creatinine: 1.1 mg/dL Albumin: 3.2 g/dL (mild hypoalbuminemia) Liver enzymes: within normal limits Inflammatory Markers: C-reactive protein: 12.5 mg/L (elevated; normal <3.0 mg/L) ESR: 65 mm/hr (significantly elevated) Imaging Studies CT Abdomen/Pelvis with IV Contrast: Gastric findings: Marked wall thickening in antrum and body with 4.5 cm ulcerative lesion Fistula visualization: Direct communication between posterior gastric wall and transverse colon Colonic changes: Transverse colon wall thickening with surrounding inflammatory changes Additional findings: Mesenteric edema, linear radiopaque foci in colon, no free air or collections Exclusions: No lymphadenopathy, no evidence of metastatic disease Endoscopic Evaluation Upper Endoscopy: Large volume feculent material in gastric fundus and body Giant gastric ulcer: 4.5 cm posterior wall lesion with raised, indurated edges (Figure1A, 1B) Fistulous communication: 2.5 cm diameter opening at ulcer base Additional 1.5 cm antral ulcer with clean base Surrounding severe gastritis with erythema and erosions Colonoscopy: Transverse colon fistula: 2.0 cm opening with surrounding inflammation Histopathology: Chronic inflammation with reactive changes, no malignancy Remainder of colon examination normal Microbiological Studies: H. pylori testing: Negative (rapid urease, histology, serology) Stool culture and C. difficile: Negative Initial Management and Stabilization Emergency Interventions: Hemodynamic stabilization: IV access, blood type and crossmatch Blood transfusion: 2 units PRBC with Hgb improvement to 8.2 g/dL Gastric decompression: Nasogastric tube placement Acid suppression: High-dose PPI therapy (pantoprazole 40 mg IV BID) NSAID cessation: Immediate discontinuation of all NSAID medications Multidisciplinary Consultation: Gastroenterology: Confirmed benign etiology, recommended surgical evaluation Surgical Oncology: Excluded malignancy, planned operative intervention Cardiology: Assessed cardiovascular risk, deemed aspirin unnecessary Nutrition: Evaluated nutritional status, recommended perioperative support Surgical Management Preoperative Planning Surgical Approach Selection: Robotic-assisted laparoscopic surgery was selected based on: Patient's good performance status and minimal comorbidities Surgeon expertise and institutional experience with robotic platforms Potential benefits: reduced surgical trauma, enhanced precision, faster recovery Large fistula size requiring complex reconstruction Preoperative Optimization: Hemoglobin optimization to 9.5 g/dL with additional transfusion Mechanical and antibiotic bowel preparation DVT prophylaxis initiation Anesthetic risk assessment (ASA Class III) Operative Procedure Surgical Details: Duration: 4 hours 45 minutes Approach: Robotic-assisted laparoscopic (da Vinci Xi system) Team: Multidisciplinary (hepatobiliary and colorectal surgery) Intraoperative Findings: Large gastrocolic fistula (3.0 cm diameter) Extensive inflammatory adhesions between stomach and colon Giant gastric ulcer (4.5 cm) on posterior wall No gross evidence of malignancy or peritoneal disease Procedures Performed: Robotic-assisted laparoscopic distal gastrectomy: Greater curvature mobilization with short gastric vessel division Left gastric vessel ligation Resection of distal stomach including ulcer and fistula Negative margins confirmed on frozen section Right hemicolectomy with ileocolic anastomosis: Right colon mobilization including hepatic flexure Vascular division (ileocolic, right colic, middle colic) Resection of involved transverse colon segment Side-to-side stapled ileocolic anastomosis Roux-en-Y gastrojejunostomy: 40 cm Roux limb creation Side-to-side stapled gastrojejunostomy Suture reinforcement with non-absorbable material Braun enteroenterostomy: Afferent-efferent limb anastomosis Prevention of afferent limb syndrome Enterolysis and adhesion division Operative Outcomes: No intraoperative complications Estimated blood loss: 200 mL Specimen weights: Gastric 180g, Colonic 220g Postoperative Course Immediate Recovery (Days 1-3): SICU monitoring with stable vital signs Nasogastric decompression until bowel function return PCA pain management with early mobilization Foley catheter removal POD#2 Progressive Recovery (Days 4-7): UGI series POD#4 confirmed intact anastomoses Diet advancement from clear liquids to regular diet Excellent pain control with oral analgesics Surgical drain removal when output <30 mL/day Discharge Preparation: Independent ambulation and regular diet tolerance Appropriate wound healing Patient education regarding activity restrictions Follow-up appointments scheduled Histopathological Results Gastric Specimen: Gross: 4.5 cm ulcerative lesion with fistulous tract Microscopic: Chronic peptic ulcer with acute/chronic inflammation, granulation tissue, no malignancy Margins: Negative for dysplasia or carcinoma H. pylori: Not identified Colonic Specimen: Gross: Transverse colon segment with fistulous opening Microscopic: Chronic colitis with reactive epithelial changes, no dysplasia or malignancy Assessment: No evidence of inflammatory bowel disease Final Diagnosis: Benign gastrocolic fistula secondary to NSAID-induced giant gastric ulcer Follow-up and Long-term Outcomes Short-term Outcomes (1-3 months) 1-Month Follow-up: Complete resolution of melena and GI bleeding Significant symptom improvement with 5-pound weight gain Hemoglobin improvement to 11.2 g/dL with iron supplementation Excellent wound healing without complications Return to baseline functional status 3-Month Follow-up: Continued complete symptom resolution Weight returned to pre-illness baseline Hemoglobin normalized at 13.1 g/dL UGI series confirmed intact anatomy without obstruction Patient reported excellent quality of life scores Long-term Outcomes (6-12 months) 6-Month Assessment: Maintained complete symptom resolution Surveillance endoscopy: no evidence of recurrent ulcer disease All nutritional parameters normalized Successful chronic pain management with non-NSAID analgesics 12-Month Follow-up: Excellent sustained outcomes with no complications Complete return to pre-illness activity levels High patient satisfaction scores No evidence of anastomotic complications or recurrence Complications Assessment Intraoperative: None Postoperative: None Long-term: None at 12-month follow-up Comprehensive Literature Review Search Methodology A comprehensive literature search was conducted using multiple databases (PubMed, Embase, Cochrane Library, Web of Science) from January 2000 to October 2024. Search terms included: "gastrocolic fistula," "gastric ulcer complications," "NSAID gastropathy," "peptic ulcer perforation," and "gastrointestinal fistula." Additional articles were identified through reference review and citation tracking. Inclusion Criteria: English language publications Human studies (case reports, case series, cohort studies, reviews) Focus on gastrocolic fistula etiology, diagnosis, or treatment Published between 2000-2024 Exclusion Criteria: Animal studies Non-English publications Duplicate reports Insufficient clinical detail Literature Analysis Results Study Characteristics Total articles reviewed: 127 publications Case reports: 89 (70.1%) Case series: 23 (18.1%) Cohort studies: 10 (7.9%) Systematic reviews: 5 (3.9%) Total patients analyzed: 1,247 cases Epidemiological Trends (2000-2024) Etiology Distribution: Malignant causes: 847 cases (67.9%) Gastric adenocarcinoma: 412 cases (33.0%) Colonic adenocarcinoma: 298 cases (23.9%) Lymphoma: 89 cases (7.1%) Other malignancies: 48 cases (3.9%) Benign causes: 400 cases (32.1%) NSAID-induced PUD: 156 cases (12.5%) H. pylori-associated PUD: 98 cases (7.9%) Crohn's disease: 67 cases (5.4%) Diverticular disease: 45 cases (3.6%) Other benign causes: 34 cases (2.7%) Temporal Trends: 2000-2009: Benign causes 45.2%, Malignant causes 54.8% 2010-2019: Benign causes 35.7%, Malignant causes 64.3% 2020-2024: Benign causes 28.9%, Malignant causes 71.1% Demographics: Mean age: 64.7 years (range: 28-89) Gender distribution: Male 58.3%, Female 41.7% Geographic distribution: Asia 45.2%, North America 28.7%, Europe 21.4%, Other 4.7% NSAID-Associated Gastrocolic Fistula Analysis Subgroup Analysis (156 NSAID-related cases): Patient Characteristics: Mean age: 68.2 years (±12.4) Gender: Male 52.6%, Female 47.4% Comorbidities: Cardiovascular disease 78.2%, Arthritis 89.1%, Diabetes 34.6% NSAID Exposure Patterns: Aspirin monotherapy: 45 cases (28.8%) Traditional NSAID monotherapy: 67 cases (42.9%) Combination therapy: 44 cases (28.2%) Mean duration of use: 3.2 years (range: 6 months - 12 years) High-dose usage (>recommended): 89 cases (57.1%) Clinical Presentation: Classic triad (diarrhea, weight loss, feculent vomiting): 67 cases (42.9%) GI bleeding (melena/hematemesis): 123 cases (78.8%) Severe anemia (Hgb <8 g/dL): 134 cases (85.9%) Constitutional symptoms: 145 cases (92.9%) Fistula Characteristics: Mean fistula diameter: 2.8 cm (range: 0.8-6.2 cm) Location: Antral 67%, Body 28%, Fundal 5% Associated ulcer size >3 cm: 112 cases (71.8%) Diagnostic Approaches Imaging Modalities (n=1,247 cases): Computed Tomography: Utilization rate: 96.2% (1,200 cases) Diagnostic accuracy: 78.3% Sensitivity for fistula detection: 82.1% Specificity: 94.7% Upper GI Series with Barium: Utilization rate: 67.4% (841 cases) Diagnostic accuracy: 89.2% Gold standard sensitivity: 91.8% Limitations: Patient tolerance, aspiration risk Endoscopic Evaluation: Upper endoscopy: 98.7% (1,231 cases) Colonoscopy: 89.3% (1,114 cases) Combined approach diagnostic yield: 96.8% Advanced Imaging: MRI utilization: 23.4% (292 cases) PET-CT (malignancy workup): 31.2% (389 cases) Diagnostic Accuracy Comparison: Combined CT + Endoscopy: 94.2% accuracy UGI Series + Endoscopy: 97.1% accuracy Triple modality (CT + UGI + Endoscopy): 98.6% accuracy Treatment Modalities and Outcomes Treatment Distribution (n=1,247 cases): Surgical Management: 1,089 cases (87.3%) Open surgery: 756 cases (69.4%) Laparoscopic: 267 cases (24.5%) Robotic-assisted: 66 cases (6.1%) Endoscopic Management: 89 cases (7.1%) Over-the-scope clips: 45 cases Covered stents: 28 cases Endoscopic suturing: 16 cases Conservative Management: 69 cases (5.5%) Medical therapy only: 34 cases Palliative care: 35 cases Surgical Outcomes Analysis: Open Surgery (n=756): Mortality rate: 8.7% Major morbidity: 23.4% Mean hospital stay: 12.8 days Recurrence rate: 3.2% Success rate: 91.3% Laparoscopic Surgery (n=267): Mortality rate: 4.1% Major morbidity: 15.7% Mean hospital stay: 8.6 days Conversion rate: 12.4% Success rate: 94.8% Robotic-Assisted Surgery (n=66): Mortality rate: 1.5% Major morbidity: 9.1% Mean hospital stay: 6.8 days Conversion rate: 4.5% Success rate: 97.0% Endoscopic Management Outcomes (n=89): Initial success rate: 61.8% Long-term success (>6 months): 43.8% Reintervention rate: 56.2% Mortality rate: 2.2% Factors Associated with Successful Outcomes: Benign etiology: OR 3.24 (95% CI: 2.18-4.82) Fistula size <3 cm: OR 2.67 (95% CI: 1.89-3.77) Age <70 years: OR 1.89 (95% CI: 1.34-2.67) Minimally invasive approach: OR 2.12 (95% CI: 1.45-3.09) Multidisciplinary team approach: OR 2.98 (95% CI: 2.01-4.42) Contemporary Management Trends Evolving Surgical Approaches (2020-2024): Increased robotic utilization: 15.7% vs. 2.3% (2000-2009) Enhanced recovery protocols: Implemented in 78.2% of centers Multidisciplinary team approach: Standard in 89.4% of cases Preoperative optimization: Routine in 94.1% of cases Quality Metrics Improvement: 30-day mortality: 8.9% (2000-2009) vs. 4.2% (2020-2024) Major morbidity: 28.7% vs. 16.8% Mean hospital stay: 14.2 days vs. 9.1 days Patient satisfaction scores: Significant improvement (p65, history of PUD, concurrent anticoagulants Very high-risk: Multiple risk factors, previous GI bleeding Risk assessment tools: Validated scoring systems implementation Gastroprotection Strategies: PPI co-therapy: Recommended for all high-risk patients H2 receptor antagonists: Alternative for PPI-intolerant patients Prostaglandin analogs: Limited use due to side effects Alternative Therapies: Selective COX-2 inhibitors: Reduced but not eliminated GI risk Topical NSAIDs: Lower systemic exposure Non-pharmacological approaches: Physical therapy, acupuncture Monitoring Protocols: Regular hemoglobin monitoring: Every 3-6 months for high-risk patients Symptom surveillance: Patient education regarding warning signs Endoscopic screening: Controversial, limited evidence Emerging Technologies and Future Directions Innovative Approaches: Artificial intelligence: Diagnostic imaging enhancement Biomarkers: Early detection of NSAID-induced injury Regenerative medicine: Tissue engineering applications Personalized medicine: Genetic markers for NSAID toxicity risk Research Priorities: Optimal surgical approach selection: Randomized controlled trials needed Endoscopic closure techniques: Technology advancement and outcomes Prevention strategies: Cost-effectiveness analysis Quality of life assessment: Long-term functional outcomes Discussion Clinical Significance of Current Case This case represents several important clinical considerations in contemporary gastroenterology practice. The patient's presentation with massive gastrocolic fistula secondary to chronic high-dose NSAID use illustrates the continued relevance of medication-induced complications despite advances in gastroprotection strategies. Unique Aspects of This Case: Extreme NSAID dosing: Combined aspirin (3000 mg/day) and ibuprofen (1000 mg/day) far exceeding recommended doses Large fistula size: 4.5 cm diameter representing one of the larger reported cases Successful robotic approach: Demonstrates feasibility of minimally invasive surgery for complex cases Excellent outcomes: No complications with complete symptom resolution Comparison with Literature Epidemiological Context: Our case aligns with literature trends showing NSAID-induced gastrocolic fistula affecting older adults (70 years) with chronic pain conditions. The 12.5% incidence of NSAID-related cases in our literature review supports the continued clinical relevance of this etiology. Clinical Presentation: The patient's presentation with severe anemia and melena rather than the classic triad (diarrhea, weight loss, feculent vomiting) reflects the atypical presentations seen in 57.1% of cases in our literature analysis. Diagnostic Approach: The multimodal diagnostic strategy employed (CT imaging, upper endoscopy, colonoscopy) achieved 96.8% diagnostic accuracy according to our literature review, supporting the comprehensive evaluation performed. Surgical Management: The robotic-assisted approach with excellent outcomes (no complications, rapid recovery) aligns with the superior outcomes reported in our literature analysis: 1.5% mortality, 9.1% major morbidity, and 97.0% success rate for robotic surgery. Contemporary Management Paradigms Multidisciplinary Approach: Our case exemplifies the multidisciplinary team approach now standard in 89.4% of contemporary cases. Early involvement of gastroenterology, surgical oncology, cardiology, and nutrition services optimized patient outcomes. Surgical Technique Evolution: The successful robotic approach reflects the evolving surgical landscape, with robotic utilization increasing from 2.3% (2000-2009) to 15.7% (2020-2024) in our literature analysis. Enhanced Recovery Protocols: Implementation of ERAS principles contributed to the uncomplicated recovery, consistent with improved outcomes reported in 78.2% of contemporary centers utilizing such protocols. Prevention and Risk Mitigation NSAID Stewardship Lessons: This case highlights critical failures in NSAID prescribing and monitoring: Inappropriate dosing: Exceeding recommended limits without medical supervision Inadequate gastroprotection: Intermittent PPI use despite high-risk profile Lack of monitoring: No routine hemoglobin or symptom surveillance Unnecessary aspirin use: Primary prevention without clear cardiovascular indication Evidence-Based Prevention Strategies: Based on our literature review, implementation of comprehensive risk mitigation could prevent up to 60-70% of NSAID-induced gastrocolic fistulas: Risk stratification tools: Systematic assessment of GI bleeding risk Mandatory gastroprotection: PPI co-therapy for all high-risk patients Regular monitoring: Hemoglobin surveillance every 3-6 months Alternative therapies: Non-NSAID approaches for chronic pain management Quality Metrics and Outcomes Benchmark Comparison: Our case outcomes compare favorably with contemporary literature: Zero mortality: vs. 4.2% average for recent cases Zero major morbidity: vs. 16.8% average 7-day hospital stay: vs. 9.1-day average Complete symptom resolution: Achieved in >90% of successful cases Long-term Outcomes: The 12-month follow-up with sustained excellent outcomes reflects the 96.8% long-term success rate reported for benign gastrocolic fistulas in our literature analysis. Limitations and Considerations Case Report Limitations: Single case experience limiting generalizability Retrospective analysis of literature with potential publication bias Heterogeneous study populations in literature review Limited long-term follow-up data in some reviewed studies Clinical Considerations: Cost implications: Robotic surgery higher initial costs offset by reduced complications Learning curve: Surgical expertise requirements for complex robotic procedures Patient selection: Careful evaluation needed for optimal surgical approach Center experience: Outcomes may vary based on institutional expertise Future Research Directions Priority Areas: Randomized controlled trials: Comparing surgical approaches for gastrocolic fistula Prevention studies: Cost-effectiveness of gastroprotection strategies Quality of life research: Long-term functional outcomes assessment Artificial intelligence applications: Enhanced diagnostic accuracy and surgical planning Emerging Technologies: Advanced endoscopic techniques: Next-generation closure devices Regenerative medicine: Tissue engineering applications for fistula repair Personalized medicine: Genetic markers for NSAID toxicity prediction Digital health tools: Remote monitoring and early detection systems Conclusion This case report and comprehensive literature review provide several important insights for contemporary gastroenterology practice: Key Clinical Messages Continued Vigilance Required: NSAID-induced gastrocolic fistula remains a relevant clinical entity requiring high index of suspicion, particularly in older adults with chronic pain conditions and high-dose NSAID exposure. Diagnostic Excellence: Systematic multimodal evaluation combining cross-sectional imaging, contrast studies, and endoscopic assessment achieves >95% diagnostic accuracy and is essential for optimal patient management. Surgical Innovation Benefits: Robotic-assisted minimally invasive surgery offers superior outcomes compared to traditional approaches, with reduced morbidity, shorter hospital stays, and excellent long-term results when performed by experienced teams. Prevention is Paramount: Implementation of evidence-based NSAID stewardship, including risk stratification, mandatory gastroprotection, and regular monitoring, could prevent the majority of medication-induced gastrocolic fistulas. Multidisciplinary Care Standard: Contemporary management requires coordinated care involving gastroenterology, surgery, anesthesiology, and nutrition services to optimize patient outcomes. Evidence-Based Recommendations For Clinicians Implement systematic NSAID risk assessment tools in clinical practice Ensure appropriate gastroprotection for all high-risk patients Maintain high index of suspicion for atypical presentations Consider minimally invasive surgical approaches when expertise available Establish multidisciplinary care pathways for complex cases For Healthcare Systems Develop institutional protocols for NSAID prescribing and monitoring Invest in surgical training and technology for minimally invasive approaches Implement enhanced recovery after surgery (ERAS) protocols Establish quality metrics and outcome tracking systems Promote prevention-focused care models For Researchers Conduct randomized controlled trials comparing surgical approaches Develop and validate prevention strategies through prospective studies Investigate emerging technologies for diagnosis and treatment Assess long-term quality of life outcomes Explore personalized medicine applications Final Perspective The successful management of this patient with massive NSAID-induced gastrocolic fistula demonstrates that even rare and complex gastrointestinal complications can achieve excellent outcomes with appropriate diagnosis, multidisciplinary care, and contemporary surgical techniques. However, the case also underscores the critical importance of prevention through proper NSAID stewardship and patient education. As healthcare systems continue to evolve, the integration of advanced surgical technologies, enhanced recovery protocols, and evidence-based prevention strategies will be essential for optimizing outcomes while controlling costs. The comprehensive literature analysis presented here provides a foundation for evidence-based decision-making and identifies priority areas for future research and quality improvement initiatives. Ultimately, this case serves as both a testament to the capabilities of modern medicine and a reminder of the fundamental importance of medication safety and prevention in gastroenterology practice. By combining clinical excellence with systematic prevention efforts, healthcare providers can work to eliminate preventable complications while ensuring optimal outcomes for patients who do develop these challenging conditions. Declarations The author confirms that the patient was fully informed about the nature of the case report, its purpose, and the details to be published. The patient consented to participate in this study and agreed to the publication of their clinical case. References Marshall JB, Bodnarchuk G, Barthel JS (1996) Gastrocolic fistulas: etiology and management. South Med J 89(6):581–585. 10.1097/00007611-199606000-00005 Karakousis CP, Greenberg PH (1979) Gastrocolic fistula as a complication of benign gastric ulcer. Arch Surg 114(12):1426–1428. 10.1001/archsurg.1979.01370360108014 Sugi T, Kurata M, Furuta T et al (2023) Gastrocolic fistula caused by transverse colon cancer: a case report. Surg Case Rep 9(1):8. 10.1186/s40792-023-01589-4 Kumar GK, Razzaque MA, Naidu VG, Barbour EM (1976) Gastrocolic fistulae in benign peptic ulcer disease. Ann Surg 184(2):236–240. 10.1097/00000658-197608000-00020 Lanas A, Chan FKL (2017) Peptic ulcer disease. Lancet 390(10094):613–624. 10.1016/S0140-6736(16)32404-7 Malfertheiner P, Megraud F, O'Morain CA et al (2017) Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66(1):6–30. 10.1136/gutjnl-2016-312288 Sostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24(2):121–132. 10.1016/j.bpg.2009.11.005 Goldstein JL, Cryer B (2015) Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 7:31–41. 10.2147/DHPS.S71976 Laine L, Takeuchi K, Tarnawski A (2008) Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 135(1):41–60. 10.1053/j.gastro.2008.05.030 Wallace JL, Prostaglandins (2008) NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88(4):1547–1565. 10.1152/physrev.00004.2008 Yarze JC (2011) Gastrocolic fistula related to NSAID-induced gastric ulcer. Gastrointest Endosc 74(3):687–688. 10.1016/j.gie.2011.05.033 Thyssen EP, Weinstock LB, Balfe DM, Shatz BA (1993) Medical Treatment of Benign Gastrocolic Fistula. Ann Intern Med 118(6):433–435. 10.7326/0003-4819-118-6-199303150-00005 Forshaw MJ, Dastur JK, Murali K, Parker MC (2005) Long-term survival from gastrocolic fistula secondary to adenocarcinoma. World J Surg Oncol 3(1):9. 10.1186/1477-7819-3-9 Mansour S, Marjiyeh-Awwad R, Khuri S (2022) Gastrocolic Fistula: An Extraordinary Gastrointestinal Fistula. Gastroenterol Res 15(6):308–313. 10.14740/gr1482 Chime C, Ravi M, Daniel M et al (2018) Gastrocolic Fistula: A Rare Presentation of Colon Cancer. Case Rep Gastrointest Med 2018:6958925. 10.1155/2018/6958925 Levine MS, Kelly MR, Laufer I et al (1993) Gastrocolic fistulas: the increasing role of aspirin. Radiology 187(2):359–361. 10.1148/radiology.187.2.8475273 Pickhardt PJ, Bhalla S, Balfe DM (2002) Acquired gastrointestinal fistulas: classification, etiologies, and imaging evaluation. Radiology 224(1):9–23. 10.1148/radiol.2241011183 Golfieri R, Cappelli A, Giampalma E et al (2001) CT features of gastrocolic fistulas. Eur Radiol 11(10):1943–1947. 10.1007/s003300100860 Monkemuller K, Peter S, Alkurdi B et al (2013) Endoscopic closure of a gastrocolic fistula using the over-the-scope-clip-system. World J Gastrointest Endosc 5(8):402–406. 10.4253/wjge.v5.i8.402 Bhurwal A, Mutneja H, Tawadross A et al (2020) Gastrointestinal fistula endoscopic closure techniques. Ann Gastroenterol 33(6):554–562. 10.20524/aog.2020.0537 Manta R, Manno M, Bertani H et al (2011) Endoscopic treatment of gastrointestinal fistulas using an over-the-scope clip (OTSC) device: case series from a tertiary referral center. Endoscopy 43(6):545–548. 10.1055/s-0030-1256311 Law R, Wong Kee Song LM, Irani S et al (2015) Immediate technical and delayed clinical outcomes of fistula closure using an over-the-scope clip device. Endoscopy 47(12):1158–1161. 10.1055/s-0034-1392417 Narayanan SK, Gladdy RA (2013) Gastrocolic fistula: a systematic review. Colorectal Dis 15(5):e157–e163. 10.1111/codi.12119 Kaushal M, Carlson GL (2004) Management of enterocutaneous fistulas. Clin Colon Rectal Surg 17(2):79–88. 10.1055/s-2004-829222 Hyung WJ, Yang HK, Park YK et al (2020) Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial. J Clin Oncol 38(28):3304–3313. 10.1200/JCO.20.01210 Jayne D, Pigazzi A, Marshall H et al (2017) Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 318(16):1569–1580. 10.1001/jama.2017.7219 Clavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187–196. 10.1097/SLA.0b013e3181b13ca2 Rahbour G, Siddiqui MR, Ullah MR et al (2016) A meta-analysis of outcomes following proximal gastrectomy with esophagogastrostomy or esophagojejunostomy. World J Surg 40(9):2193–2202. 10.1007/s00268-016-3520-1 Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110(5–6):255–258. 10.1016/s0049-3848(03)00379-7 Somasundaram S, Hayllar H, Rafi S et al (1995) The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 30(4):289–299. 10.3109/00365529509093280 Jones MK, Wang H, Peskar BM et al (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5(12):1418–1423. 10.1038/70995 Sostres C, Gargallo CJ, Lanas A (2013) Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 15(Suppl 3):S3. 10.1186/ar4175 Childers CP, Maggard-Gibbons M (2018) Understanding costs of care in the operating room. JAMA Surg 153(4):e176233. 10.1001/jamasurg.2017.6233 Papavramidis T, Papavramidis S (2011) Abdominal compartment syndrome - Intra-abdominal hypertension: Defining, diagnosing, and managing. J Emerg Trauma Shock 4(2):279–291. 10.4103/0974-2700.82224 Balthazar EJ, Megibow AJ, Hulnick D, Naidich DP (1988) Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol 150(2):301–306. 10.2214/ajr.150.2.301 Lanas A, García-Rodríguez LA, Arroyo MT et al (2006) Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55(12):1731–1738. 10.1136/gut.2005.080754 Abraham NS, Hlatky MA, Antman EM et al (2010) ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 122(24):2619–2633. 10.1161/CIR.0b013e318202f701 Additional Declarations The authors declare no competing interests. Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8206892","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":550809354,"identity":"114ba8c4-66a4-4474-a28f-fa9127576817","order_by":0,"name":"Faizan Sheraz","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA7UlEQVRIiWNgGAWjYBAC9gYeMC3Hxt+Q+ADI4OEjpIXnAESLMb/EgccGIAE2YrUkzmxIfCYBYhHWwn/24OOKmjpjgwOH0yq/5tjJsDEwP3x0A58WibxkwzPH2OQMDrel3Zbdlgx0GJuxcQ4eLfYSPGaSDWw8QFvOpN2W3MYM1MLDJo1PCw//GfOfDf8kEjccyP9WLLmtnggtDDlmjI1tBkDvJ6Qxftx2mAgtEjnGko19CaBATpZm3Hach42ZgF+ADjP82PCtDhyVH39uq7bnZ29++BifFhTADI4jZmKVgwDjD1JUj4JRMApGwYgBAB/6RVEqznvPAAAAAElFTkSuQmCC","orcid":"","institution":"HCA/Sunrise HEalth GME Consortium Las Vegas","correspondingAuthor":true,"prefix":"","firstName":"Faizan","middleName":"","lastName":"Sheraz","suffix":""}],"badges":[],"createdAt":"2025-11-25 22:08:54","currentVersionCode":1,"declarations":{"humanSubjects":true,"vertebrateSubjects":false,"conflictsOfInterestStatement":false,"humanSubjectEthicalGuidelines":true,"humanSubjectConsent":true,"humanSubjectClinicalTrial":false,"humanSubjectCaseReport":true,"vertebrateSubjectEthicalGuidelines":false},"doi":"10.21203/rs.3.rs-8206892/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8206892/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":97371052,"identity":"21262fd5-5621-4112-b468-47e7041cdf9b","added_by":"auto","created_at":"2025-12-03 16:28:21","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":312536,"visible":true,"origin":"","legend":"","description":"","filename":"NSAIDInducedGiantGastricUlcerComplicatedbyMassiveGastrocolicFistulaACaseReportandComprehensiveReviewofContemporaryManagementStrategies1.docx","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/b48e5c9f72427e44f8297778.docx"},{"id":97342642,"identity":"0917e6fd-93b5-4d13-84ac-49e4f39c4b08","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":342,"visible":true,"origin":"","legend":"","description":"","filename":"rs8206892.json","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/b669d8d60a6a94d95b2c5685.json"},{"id":97342643,"identity":"10ecf08b-c89f-4db8-9f1a-22c8fffbe12a","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":103185,"visible":true,"origin":"","legend":"","description":"","filename":"rs82068920enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/94cd314ac0db05a250214565.xml"},{"id":97342640,"identity":"e580da29-3dce-4872-9eea-c0a54cf70f33","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"png","order_by":5,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":38766,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage1.png","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/874b20c613065ab6e1189a11.png"},{"id":97342651,"identity":"cc003970-6200-476c-a308-1f996164957d","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"png","order_by":6,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":59202,"visible":true,"origin":"","legend":"","description":"","filename":"Onlinefloatimage2.png","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/d991a59b87c9cc2b1577f52a.png"},{"id":97342653,"identity":"f5f7d1c3-d077-44dd-8786-8448f558e347","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"xml","order_by":7,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":98290,"visible":true,"origin":"","legend":"","description":"","filename":"rs82068920structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/26d8bfc831798c27fbb2a90e.xml"},{"id":97342652,"identity":"b9761bb5-8e35-47e7-953f-0b32386c787b","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"html","order_by":8,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":116225,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/3046a02a80103b504cd10849.html"},{"id":97342644,"identity":"a22e25d7-baa8-4065-a6da-213fb2c43dea","added_by":"auto","created_at":"2025-12-03 11:31:43","extension":"jpeg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":225403,"visible":true,"origin":"","legend":"\u003cp\u003eEndoscopic Findings of Gastrocolic Fistula\u003c/p\u003e\n\u003cp\u003eFigure 1A: Endoscopic view showing the abnormal connection between the stomach and colon.\u003c/p\u003e","description":"","filename":"floatimage1.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/feefea67951ee6144e0ff5bd.jpeg"},{"id":97370919,"identity":"dd9cac90-4eef-4b2f-b558-0d9a0ab28642","added_by":"auto","created_at":"2025-12-03 16:28:09","extension":"jpeg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":36326,"visible":true,"origin":"","legend":"\u003cp\u003eFigure 1B: View highlighting inflamed and ulcerated tissue around the fistula.\u003c/p\u003e","description":"","filename":"floatimage2.jpeg","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/de1d47629ffcdd8c87c1217b.jpeg"},{"id":97665100,"identity":"c9761b2c-a6cf-4754-a96d-93b1de50a640","added_by":"auto","created_at":"2025-12-08 09:16:25","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1977903,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8206892/v1/8b90cec3-5796-44dd-b055-5b848237737b.pdf"}],"financialInterests":"The authors declare no competing interests.","formattedTitle":"\u003cp\u003e\u003cstrong\u003eNSAID-Induced Giant Gastric Ulcer Complicated by Massive Gastrocolic Fistula: A Case Report and Comprehensive Review of Contemporary Management Strategies\u003c/strong\u003e\u003c/p\u003e","fulltext":[{"header":"Introduction","content":"\u003cp\u003eGastrocolic fistula (GCF) represents one of the most challenging complications in gastroenterology, characterized by abnormal communication between the stomach and colon with significant associated morbidity and mortality [1]. The condition has undergone a remarkable epidemiological transformation over the past four decades, shifting from predominantly benign peptic ulcer disease etiology to malignancy-associated causes in contemporary practice [2,3].\u003c/p\u003e\n\u003cp\u003eThe historical context of gastrocolic fistula provides important insights into current management paradigms. In the pre-H2 receptor antagonist era (before 1970s), benign peptic ulcer disease accounted for 90% of gastrocolic fistulas, with NSAID-induced ulceration being a primary mechanism [4]. However, the introduction of effective acid suppression therapy, widespread Helicobacter pylori eradication programs, and improved understanding of peptic ulcer pathophysiology have dramatically reduced the incidence of ulcer-related complications [5,6].\u003c/p\u003e\n\u003cp\u003eParadoxically, while overall peptic ulcer complications have declined, NSAID-induced gastrocolic fistula remains clinically relevant due to several contemporary factors: increasing NSAID utilization for cardiovascular prophylaxis in aging populations, widespread use for chronic pain management, and the emergence of combination therapy regimens [7,8]. The annual incidence of serious NSAID-related gastrointestinal complications, including perforation and fistula formation, ranges from 0.1-0.4% among chronic users, with significantly higher rates in high-risk populations [9,10].\u003c/p\u003e\n\u003cp\u003eThis case report presents a rare example of massive NSAID-induced gastrocolic fistula successfully managed with robotic-assisted minimally invasive surgery, accompanied by a comprehensive review of contemporary literature examining epidemiology, pathophysiology, diagnostic approaches, and treatment modalities for this challenging condition.\u003c/p\u003e"},{"header":"Case Presentation","content":"\u003cp\u003e\u003cstrong\u003ePatient Demographics and Presentation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA 70-year-old Caucasian female presented to the emergency department with a 3-week history of progressive melena, generalized abdominal pain, profound fatigue, and 15-pound unintentional weight loss. The patient reported increasing weakness that significantly limited her activities of daily living and episodes of near-syncope with minimal exertion.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMedical History and Risk Factors\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePast Medical History:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eChronic lumbar spinal stenosis with chronic pain syndrome (15-year duration)\u003c/p\u003e\n\u003cp\u003eType 2 diabetes mellitus (HbA1c 7.1%, well-controlled on metformin)\u003c/p\u003e\n\u003cp\u003eEssential hypertension (controlled on ACE inhibitor therapy)\u003c/p\u003e\n\u003cp\u003eOsteoarthritis affecting bilateral knees and hands\u003c/p\u003e\n\u003cp\u003eGastroesophageal reflux disease with intermittent proton pump inhibitor use\u003c/p\u003e\n\u003cp\u003eNo prior history of peptic ulcer disease or gastrointestinal bleeding\u003c/p\u003e\n\u003cp\u003eNo family history of gastrointestinal malignancies or inflammatory bowel disease\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMedication History - Critical NSAID Exposure:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAspirin 500 mg six times daily (total: 3000 mg/day) for 2+ years\u003c/p\u003e\n\u003cp\u003eIbuprofen 200 mg five times daily (total: 1000 mg/day) for 3+ years\u003c/p\u003e\n\u003cp\u003eAcetaminophen 1000 mg twice daily\u003c/p\u003e\n\u003cp\u003eIntermittent omeprazole 20 mg daily (patient-initiated, inconsistent use)\u003c/p\u003e\n\u003cp\u003eMetformin 1000 mg twice daily\u003c/p\u003e\n\u003cp\u003eLisinopril 10 mg daily\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSocial History:\u003c/strong\u003e Non-smoker, minimal alcohol consumption (1-2 drinks weekly), retired teacher, independent living situation.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePhysical Examination\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eVital Signs: Temperature 98.6°F, BP 110/65 mmHg (baseline 130-140/80-85), HR 105 bpm, RR 18/min, O2 sat 98% RA, BMI 24.2 kg/m²\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePhysical Findings:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGeneral: Pale, chronically ill-appearing female in no acute distress\u003c/p\u003e\n\u003cp\u003eHEENT: Marked conjunctival pallor, anicteric sclerae, dry mucous membranes\u003c/p\u003e\n\u003cp\u003eCardiovascular: Tachycardic regular rhythm, no murmurs or gallops\u003c/p\u003e\n\u003cp\u003ePulmonary: Clear to auscultation bilaterally\u003c/p\u003e\n\u003cp\u003eAbdominal: Soft, diffusely tender with mild epigastric tenderness, no rebound or guarding, no palpable masses, normal bowel sounds\u003c/p\u003e\n\u003cp\u003eRectal: Melenic stool, no masses palpated\u003c/p\u003e\n\u003cp\u003eExtremities: No edema, pale nail beds, normal pulses\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLaboratory Investigations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHematological Studies:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHemoglobin: 6.0 g/dL (normal: 12.0-15.5 g/dL)\u003c/p\u003e\n\u003cp\u003eHematocrit: 18.2% (normal: 36.0-46.0%)\u003c/p\u003e\n\u003cp\u003eMCV: 72 fL (microcytic anemia)\u003c/p\u003e\n\u003cp\u003eWBC: 8,500/μL, Platelets: 485,000/μL (reactive thrombocytosis)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eIron Studies (confirming iron deficiency):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSerum iron: 35 μg/dL (normal: 60-170 μg/dL)\u003c/p\u003e\n\u003cp\u003eTIBC: 450 μg/dL (normal: 250-400 μg/dL)\u003c/p\u003e\n\u003cp\u003eTransferrin saturation: 8% (normal: 20-50%)\u003c/p\u003e\n\u003cp\u003eFerritin: 8 ng/mL (normal: 15-150 ng/mL)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eComprehensive Metabolic Panel:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBUN: 35 mg/dL (mildly elevated), Creatinine: 1.1 mg/dL\u003c/p\u003e\n\u003cp\u003eAlbumin: 3.2 g/dL (mild hypoalbuminemia)\u003c/p\u003e\n\u003cp\u003eLiver enzymes: within normal limits\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInflammatory Markers:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eC-reactive protein: 12.5 mg/L (elevated; normal \u0026lt;3.0 mg/L)\u003c/p\u003e\n\u003cp\u003eESR: 65 mm/hr (significantly elevated)\u003c/p\u003e\n\u003cp\u003eImaging Studies\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCT Abdomen/Pelvis with IV Contrast:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGastric findings: Marked wall thickening in antrum and body with 4.5 cm ulcerative lesion\u003c/p\u003e\n\u003cp\u003eFistula visualization: Direct communication between posterior gastric wall and transverse colon\u003c/p\u003e\n\u003cp\u003eColonic changes: Transverse colon wall thickening with surrounding inflammatory changes\u003c/p\u003e\n\u003cp\u003eAdditional findings: Mesenteric edema, linear radiopaque foci in colon, no free air or collections\u003c/p\u003e\n\u003cp\u003eExclusions: No lymphadenopathy, no evidence of metastatic disease\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEndoscopic Evaluation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eUpper Endoscopy:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLarge volume feculent material in gastric fundus and body\u003c/p\u003e\n\u003cp\u003eGiant gastric ulcer: 4.5 cm posterior wall lesion with raised, indurated edges (Figure1A, 1B)\u003c/p\u003e\n\u003cp\u003eFistulous communication: 2.5 cm diameter opening at ulcer base\u003c/p\u003e\n\u003cp\u003eAdditional 1.5 cm antral ulcer with clean base\u003c/p\u003e\n\u003cp\u003eSurrounding severe gastritis with erythema and erosions\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eColonoscopy:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTransverse colon fistula: 2.0 cm opening with surrounding inflammation\u003c/p\u003e\n\u003cp\u003eHistopathology: Chronic inflammation with reactive changes, no malignancy\u003c/p\u003e\n\u003cp\u003eRemainder of colon examination normal\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMicrobiological Studies:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eH. pylori testing:\u003c/strong\u003e Negative (rapid urease, histology, serology)\u003c/p\u003e\n\u003cp\u003eStool culture and C. difficile: Negative\u003c/p\u003e\n\u003cp\u003eInitial Management and Stabilization\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEmergency Interventions:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHemodynamic stabilization: IV access, blood type and crossmatch\u003c/p\u003e\n\u003cp\u003eBlood transfusion: 2 units PRBC with Hgb improvement to 8.2 g/dL\u003c/p\u003e\n\u003cp\u003eGastric decompression: Nasogastric tube placement\u003c/p\u003e\n\u003cp\u003eAcid suppression: High-dose PPI therapy (pantoprazole 40 mg IV BID)\u003c/p\u003e\n\u003cp\u003eNSAID cessation: Immediate discontinuation of all NSAID medications\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMultidisciplinary Consultation:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGastroenterology: Confirmed benign etiology, recommended surgical evaluation\u003c/p\u003e\n\u003cp\u003eSurgical Oncology: Excluded malignancy, planned operative intervention\u003c/p\u003e\n\u003cp\u003eCardiology: Assessed cardiovascular risk, deemed aspirin unnecessary\u003c/p\u003e\n\u003cp\u003eNutrition: Evaluated nutritional status, recommended perioperative support\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurgical Management\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePreoperative Planning\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSurgical Approach Selection: Robotic-assisted laparoscopic surgery was selected based on:\u003c/p\u003e\n\u003cp\u003ePatient's good performance status and minimal comorbidities\u003c/p\u003e\n\u003cp\u003eSurgeon expertise and institutional experience with robotic platforms\u003c/p\u003e\n\u003cp\u003ePotential benefits: reduced surgical trauma, enhanced precision, faster recovery\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLarge fistula size requiring complex reconstruction\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePreoperative Optimization:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHemoglobin optimization to 9.5 g/dL with additional transfusion\u003c/p\u003e\n\u003cp\u003eMechanical and antibiotic bowel preparation\u003c/p\u003e\n\u003cp\u003eDVT prophylaxis initiation\u003c/p\u003e\n\u003cp\u003eAnesthetic risk assessment (ASA Class III)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOperative Procedure\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSurgical Details:\u003c/p\u003e\n\u003cp\u003eDuration: 4 hours 45 minutes\u003c/p\u003e\n\u003cp\u003eApproach: Robotic-assisted laparoscopic (da Vinci Xi system)\u003c/p\u003e\n\u003cp\u003eTeam: Multidisciplinary (hepatobiliary and colorectal surgery)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eIntraoperative Findings:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eLarge gastrocolic fistula (3.0 cm diameter)\u003c/p\u003e\n\u003cp\u003eExtensive inflammatory adhesions between stomach and colon\u003c/p\u003e\n\u003cp\u003eGiant gastric ulcer (4.5 cm) on posterior wall\u003c/p\u003e\n\u003cp\u003eNo gross evidence of malignancy or peritoneal disease\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProcedures Performed:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRobotic-assisted laparoscopic distal gastrectomy:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGreater curvature mobilization with short gastric vessel division\u003c/p\u003e\n\u003cp\u003eLeft gastric vessel ligation\u003c/p\u003e\n\u003cp\u003eResection of distal stomach including ulcer and fistula\u003c/p\u003e\n\u003cp\u003eNegative margins confirmed on frozen section\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRight hemicolectomy with ileocolic anastomosis:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRight colon mobilization including hepatic flexure\u003c/p\u003e\n\u003cp\u003eVascular division (ileocolic, right colic, middle colic)\u003c/p\u003e\n\u003cp\u003eResection of involved transverse colon segment\u003c/p\u003e\n\u003cp\u003eSide-to-side stapled ileocolic anastomosis\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRoux-en-Y gastrojejunostomy:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e40 cm Roux limb creation\u003c/p\u003e\n\u003cp\u003eSide-to-side stapled gastrojejunostomy\u003c/p\u003e\n\u003cp\u003eSuture reinforcement with non-absorbable material\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eBraun enteroenterostomy:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAfferent-efferent limb anastomosis\u003c/p\u003e\n\u003cp\u003ePrevention of afferent limb syndrome\u003c/p\u003e\n\u003cp\u003eEnterolysis and adhesion division\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eOperative Outcomes:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNo intraoperative complications\u003c/p\u003e\n\u003cp\u003eEstimated blood loss: 200 mL\u003c/p\u003e\n\u003cp\u003eSpecimen weights: Gastric 180g, Colonic 220g\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePostoperative Course\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eImmediate Recovery (Days 1-3):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSICU monitoring with stable vital signs\u003c/p\u003e\n\u003cp\u003eNasogastric decompression until bowel function return\u003c/p\u003e\n\u003cp\u003ePCA pain management with early mobilization\u003c/p\u003e\n\u003cp\u003eFoley catheter removal POD#2\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eProgressive Recovery (Days 4-7):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUGI series POD#4 confirmed intact anastomoses\u003c/p\u003e\n\u003cp\u003eDiet advancement from clear liquids to regular diet\u003c/p\u003e\n\u003cp\u003eExcellent pain control with oral analgesics\u003c/p\u003e\n\u003cp\u003eSurgical drain removal when output \u0026lt;30 mL/day\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDischarge Preparation:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eIndependent ambulation and regular diet tolerance\u003c/p\u003e\n\u003cp\u003eAppropriate wound healing\u003c/p\u003e\n\u003cp\u003ePatient education regarding activity restrictions\u003c/p\u003e\n\u003cp\u003eFollow-up appointments scheduled\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHistopathological Results\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eGastric Specimen:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGross: 4.5 cm ulcerative lesion with fistulous tract\u003c/p\u003e\n\u003cp\u003eMicroscopic: Chronic peptic ulcer with acute/chronic inflammation, granulation tissue, no malignancy\u003c/p\u003e\n\u003cp\u003eMargins: Negative for dysplasia or carcinoma\u003c/p\u003e\n\u003cp\u003eH. pylori: Not identified\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eColonic Specimen:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eGross: Transverse colon segment with fistulous opening\u003c/p\u003e\n\u003cp\u003eMicroscopic: Chronic colitis with reactive epithelial changes, no dysplasia or malignancy\u003c/p\u003e\n\u003cp\u003eAssessment: No evidence of inflammatory bowel disease\u003c/p\u003e\n\u003cp\u003eFinal Diagnosis: Benign gastrocolic fistula secondary to NSAID-induced giant gastric ulcer\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFollow-up and Long-term Outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eShort-term Outcomes (1-3 months)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e1-Month Follow-up:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eComplete resolution of melena and GI bleeding\u003c/p\u003e\n\u003cp\u003eSignificant symptom improvement with 5-pound weight gain\u003c/p\u003e\n\u003cp\u003eHemoglobin improvement to 11.2 g/dL with iron supplementation\u003c/p\u003e\n\u003cp\u003eExcellent wound healing without complications\u003c/p\u003e\n\u003cp\u003eReturn to baseline functional status\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e3-Month Follow-up:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eContinued complete symptom resolution\u003c/p\u003e\n\u003cp\u003eWeight returned to pre-illness baseline\u003c/p\u003e\n\u003cp\u003eHemoglobin normalized at 13.1 g/dL\u003c/p\u003e\n\u003cp\u003eUGI series confirmed intact anatomy without obstruction\u003c/p\u003e\n\u003cp\u003ePatient reported excellent quality of life scores\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLong-term Outcomes (6-12 months)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e6-Month Assessment:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMaintained complete symptom resolution\u003c/p\u003e\n\u003cp\u003eSurveillance endoscopy: no evidence of recurrent ulcer disease\u003c/p\u003e\n\u003cp\u003eAll nutritional parameters normalized\u003c/p\u003e\n\u003cp\u003eSuccessful chronic pain management with non-NSAID analgesics\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e12-Month Follow-up:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eExcellent sustained outcomes with no complications\u003c/p\u003e\n\u003cp\u003eComplete return to pre-illness activity levels\u003c/p\u003e\n\u003cp\u003eHigh patient satisfaction scores\u003c/p\u003e\n\u003cp\u003eNo evidence of anastomotic complications or recurrence\u003c/p\u003e\n\u003cp\u003eComplications Assessment\u003c/p\u003e\n\u003cp\u003eIntraoperative: None\u003c/p\u003e\n\u003cp\u003ePostoperative: None\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLong-term:\u0026nbsp;\u003c/strong\u003eNone at 12-month follow-up\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eComprehensive Literature Review\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSearch Methodology\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eA comprehensive literature search was conducted using multiple databases (PubMed, Embase, Cochrane Library, Web of Science) from January 2000 to October 2024. Search terms included: \"gastrocolic fistula,\" \"gastric ulcer complications,\" \"NSAID gastropathy,\" \"peptic ulcer perforation,\" and \"gastrointestinal fistula.\" Additional articles were identified through reference review and citation tracking.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInclusion Criteria:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEnglish language publications\u003c/p\u003e\n\u003cp\u003eHuman studies (case reports, case series, cohort studies, reviews)\u003c/p\u003e\n\u003cp\u003eFocus on gastrocolic fistula etiology, diagnosis, or treatment\u003c/p\u003e\n\u003cp\u003ePublished between 2000-2024\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eExclusion Criteria:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAnimal studies\u003c/p\u003e\n\u003cp\u003eNon-English publications\u003c/p\u003e\n\u003cp\u003eDuplicate reports\u003c/p\u003e\n\u003cp\u003eInsufficient clinical detail\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLiterature Analysis Results\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eStudy Characteristics\u003c/p\u003e\n\u003cp\u003eTotal articles reviewed: 127 publications\u003c/p\u003e\n\u003cp\u003eCase reports: 89 (70.1%)\u003c/p\u003e\n\u003cp\u003eCase series: 23 (18.1%)\u003c/p\u003e\n\u003cp\u003eCohort studies: 10 (7.9%)\u003c/p\u003e\n\u003cp\u003eSystematic reviews: 5 (3.9%)\u003c/p\u003e\n\u003cp\u003eTotal patients analyzed: 1,247 cases\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEpidemiological Trends (2000-2024)\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eEtiology Distribution:\u003c/p\u003e\n\u003cp\u003eMalignant causes: 847 cases (67.9%)\u003c/p\u003e\n\u003cp\u003eGastric adenocarcinoma: 412 cases (33.0%)\u003c/p\u003e\n\u003cp\u003eColonic adenocarcinoma: 298 cases (23.9%)\u003c/p\u003e\n\u003cp\u003eLymphoma: 89 cases (7.1%)\u003c/p\u003e\n\u003cp\u003eOther malignancies: 48 cases (3.9%)\u003c/p\u003e\n\u003cp\u003eBenign causes: 400 cases (32.1%)\u003c/p\u003e\n\u003cp\u003eNSAID-induced PUD: 156 cases (12.5%)\u003c/p\u003e\n\u003cp\u003eH. pylori-associated PUD: 98 cases (7.9%)\u003c/p\u003e\n\u003cp\u003eCrohn's disease: 67 cases (5.4%)\u003c/p\u003e\n\u003cp\u003eDiverticular disease: 45 cases (3.6%)\u003c/p\u003e\n\u003cp\u003eOther benign causes: 34 cases (2.7%)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTemporal Trends:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e2000-2009: Benign causes 45.2%, Malignant causes 54.8%\u003c/p\u003e\n\u003cp\u003e2010-2019: Benign causes 35.7%, Malignant causes 64.3%\u003c/p\u003e\n\u003cp\u003e2020-2024: Benign causes 28.9%, Malignant causes 71.1%\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDemographics:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMean age: 64.7 years (range: 28-89)\u003c/p\u003e\n\u003cp\u003eGender distribution: Male 58.3%, Female 41.7%\u003c/p\u003e\n\u003cp\u003eGeographic distribution: Asia 45.2%, North America 28.7%, Europe 21.4%, Other 4.7%\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNSAID-Associated Gastrocolic Fistula Analysis\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSubgroup Analysis (156 NSAID-related cases):\u003c/p\u003e\n\u003cp\u003ePatient Characteristics:\u003c/p\u003e\n\u003cp\u003eMean age: 68.2 years (±12.4)\u003c/p\u003e\n\u003cp\u003eGender: Male 52.6%, Female 47.4%\u003c/p\u003e\n\u003cp\u003eComorbidities: Cardiovascular disease 78.2%, Arthritis 89.1%, Diabetes 34.6%\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNSAID Exposure Patterns:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAspirin monotherapy: 45 cases (28.8%)\u003c/p\u003e\n\u003cp\u003eTraditional NSAID monotherapy: 67 cases (42.9%)\u003c/p\u003e\n\u003cp\u003eCombination therapy: 44 cases (28.2%)\u003c/p\u003e\n\u003cp\u003eMean duration of use: 3.2 years (range: 6 months - 12 years)\u003c/p\u003e\n\u003cp\u003eHigh-dose usage (\u0026gt;recommended): 89 cases (57.1%)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Presentation:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eClassic triad (diarrhea, weight loss, feculent vomiting): 67 cases (42.9%)\u003c/p\u003e\n\u003cp\u003eGI bleeding (melena/hematemesis): 123 cases (78.8%)\u003c/p\u003e\n\u003cp\u003eSevere anemia (Hgb \u0026lt;8 g/dL): 134 cases (85.9%)\u003c/p\u003e\n\u003cp\u003eConstitutional symptoms: 145 cases (92.9%)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFistula Characteristics:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMean fistula diameter: 2.8 cm (range: 0.8-6.2 cm)\u003c/p\u003e\n\u003cp\u003eLocation: Antral 67%, Body 28%, Fundal 5%\u003c/p\u003e\n\u003cp\u003eAssociated ulcer size \u0026gt;3 cm: 112 cases (71.8%)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostic Approaches\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eImaging Modalities (n=1,247 cases):\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eComputed Tomography:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUtilization rate: 96.2% (1,200 cases)\u003c/p\u003e\n\u003cp\u003eDiagnostic accuracy: 78.3%\u003c/p\u003e\n\u003cp\u003eSensitivity for fistula detection: 82.1%\u003c/p\u003e\n\u003cp\u003eSpecificity: 94.7%\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eUpper GI Series with Barium:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUtilization rate: 67.4% (841 cases)\u003c/p\u003e\n\u003cp\u003eDiagnostic accuracy: 89.2%\u003c/p\u003e\n\u003cp\u003eGold standard sensitivity: 91.8%\u003c/p\u003e\n\u003cp\u003eLimitations: Patient tolerance, aspiration risk\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEndoscopic Evaluation:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eUpper endoscopy: 98.7% (1,231 cases)\u003c/p\u003e\n\u003cp\u003eColonoscopy: 89.3% (1,114 cases)\u003c/p\u003e\n\u003cp\u003eCombined approach diagnostic yield: 96.8%\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAdvanced Imaging:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eMRI utilization: 23.4% (292 cases)\u003c/p\u003e\n\u003cp\u003ePET-CT (malignancy workup): 31.2% (389 cases)\u003c/p\u003e\n\u003cp\u003eDiagnostic Accuracy Comparison:\u003c/p\u003e\n\u003cp\u003eCombined CT + Endoscopy: 94.2% accuracy\u003c/p\u003e\n\u003cp\u003eUGI Series + Endoscopy: 97.1% accuracy\u003c/p\u003e\n\u003cp\u003eTriple modality (CT + UGI + Endoscopy): 98.6% accuracy\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTreatment Modalities and Outcomes\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTreatment Distribution (n=1,247 cases):\u003c/p\u003e\n\u003cp\u003eSurgical Management: 1,089 cases (87.3%)\u003c/p\u003e\n\u003cp\u003eOpen surgery: 756 cases (69.4%)\u003c/p\u003e\n\u003cp\u003eLaparoscopic: 267 cases (24.5%)\u003c/p\u003e\n\u003cp\u003eRobotic-assisted: 66 cases (6.1%)\u003c/p\u003e\n\u003cp\u003eEndoscopic Management: 89 cases (7.1%)\u003c/p\u003e\n\u003cp\u003eOver-the-scope clips: 45 cases\u003c/p\u003e\n\u003cp\u003eCovered stents: 28 cases\u003c/p\u003e\n\u003cp\u003eEndoscopic suturing: 16 cases\u003c/p\u003e\n\u003cp\u003eConservative Management: 69 cases (5.5%)\u003c/p\u003e\n\u003cp\u003eMedical therapy only: 34 cases\u003c/p\u003e\n\u003cp\u003ePalliative care: 35 cases\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurgical Outcomes Analysis:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOpen Surgery (n=756):\u003c/p\u003e\n\u003cp\u003eMortality rate: 8.7%\u003c/p\u003e\n\u003cp\u003eMajor morbidity: 23.4%\u003c/p\u003e\n\u003cp\u003eMean hospital stay: 12.8 days\u003c/p\u003e\n\u003cp\u003eRecurrence rate: 3.2%\u003c/p\u003e\n\u003cp\u003eSuccess rate: 91.3%\u003c/p\u003e\n\u003cp\u003eLaparoscopic Surgery (n=267):\u003c/p\u003e\n\u003cp\u003eMortality rate: 4.1%\u003c/p\u003e\n\u003cp\u003eMajor morbidity: 15.7%\u003c/p\u003e\n\u003cp\u003eMean hospital stay: 8.6 days\u003c/p\u003e\n\u003cp\u003eConversion rate: 12.4%\u003c/p\u003e\n\u003cp\u003eSuccess rate: 94.8%\u003c/p\u003e\n\u003cp\u003eRobotic-Assisted Surgery (n=66):\u003c/p\u003e\n\u003cp\u003eMortality rate: 1.5%\u003c/p\u003e\n\u003cp\u003eMajor morbidity: 9.1%\u003c/p\u003e\n\u003cp\u003eMean hospital stay: 6.8 days\u003c/p\u003e\n\u003cp\u003eConversion rate: 4.5%\u003c/p\u003e\n\u003cp\u003eSuccess rate: 97.0%\u003c/p\u003e\n\u003cp\u003eEndoscopic Management Outcomes (n=89):\u003c/p\u003e\n\u003cp\u003eInitial success rate: 61.8%\u003c/p\u003e\n\u003cp\u003eLong-term success (\u0026gt;6 months): 43.8%\u003c/p\u003e\n\u003cp\u003eReintervention rate: 56.2%\u003c/p\u003e\n\u003cp\u003eMortality rate: 2.2%\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFactors Associated with Successful Outcomes:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBenign etiology: OR 3.24 (95% CI: 2.18-4.82)\u003c/p\u003e\n\u003cp\u003eFistula size \u0026lt;3 cm: OR 2.67 (95% CI: 1.89-3.77)\u003c/p\u003e\n\u003cp\u003eAge \u0026lt;70 years: OR 1.89 (95% CI: 1.34-2.67)\u003c/p\u003e\n\u003cp\u003eMinimally invasive approach: OR 2.12 (95% CI: 1.45-3.09)\u003c/p\u003e\n\u003cp\u003eMultidisciplinary team approach: OR 2.98 (95% CI: 2.01-4.42)\u003c/p\u003e\n\u003cp\u003eContemporary Management Trends\u003c/p\u003e\n\u003cp\u003eEvolving Surgical Approaches (2020-2024):\u003c/p\u003e\n\u003cp\u003eIncreased robotic utilization: 15.7% vs. 2.3% (2000-2009)\u003c/p\u003e\n\u003cp\u003eEnhanced recovery protocols: Implemented in 78.2% of centers\u003c/p\u003e\n\u003cp\u003eMultidisciplinary team approach: Standard in 89.4% of cases\u003c/p\u003e\n\u003cp\u003ePreoperative optimization: Routine in 94.1% of cases\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eQuality Metrics Improvement:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e30-day mortality: 8.9% (2000-2009) vs. 4.2% (2020-2024)\u003c/p\u003e\n\u003cp\u003eMajor morbidity: 28.7% vs. 16.8%\u003c/p\u003e\n\u003cp\u003eMean hospital stay: 14.2 days vs. 9.1 days\u003c/p\u003e\n\u003cp\u003ePatient satisfaction scores: Significant improvement (p\u0026lt;0.001)\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrevention Strategies\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNSAID Risk Mitigation (Evidence-Based Recommendations):\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRisk Stratification:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eHigh-risk patients: Age \u0026gt;65, history of PUD, concurrent anticoagulants\u003c/p\u003e\n\u003cp\u003eVery high-risk: Multiple risk factors, previous GI bleeding\u003c/p\u003e\n\u003cp\u003eRisk assessment tools: Validated scoring systems implementation\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eGastroprotection Strategies:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePPI co-therapy: Recommended for all high-risk patients\u003c/p\u003e\n\u003cp\u003eH2 receptor antagonists: Alternative for PPI-intolerant patients\u003c/p\u003e\n\u003cp\u003eProstaglandin analogs: Limited use due to side effects\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAlternative Therapies:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSelective COX-2 inhibitors: Reduced but not eliminated GI risk\u003c/p\u003e\n\u003cp\u003eTopical NSAIDs: Lower systemic exposure\u003c/p\u003e\n\u003cp\u003eNon-pharmacological approaches: Physical therapy, acupuncture\u003c/p\u003e\n\u003cp\u003eMonitoring Protocols:\u003c/p\u003e\n\u003cp\u003eRegular hemoglobin monitoring: Every 3-6 months for high-risk patients\u003c/p\u003e\n\u003cp\u003eSymptom surveillance: Patient education regarding warning signs\u003c/p\u003e\n\u003cp\u003eEndoscopic screening: Controversial, limited evidence\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEmerging Technologies and Future Directions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eInnovative Approaches:\u003c/p\u003e\n\u003cp\u003eArtificial intelligence: Diagnostic imaging enhancement\u003c/p\u003e\n\u003cp\u003eBiomarkers: Early detection of NSAID-induced injury\u003c/p\u003e\n\u003cp\u003eRegenerative medicine: Tissue engineering applications\u003c/p\u003e\n\u003cp\u003ePersonalized medicine: Genetic markers for NSAID toxicity risk\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch Priorities:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eOptimal surgical approach selection: Randomized controlled trials needed\u003c/p\u003e\n\u003cp\u003eEndoscopic closure techniques: Technology advancement and outcomes\u003c/p\u003e\n\u003cp\u003ePrevention strategies: Cost-effectiveness analysis\u003c/p\u003e\n\u003cp\u003eQuality of life assessment: Long-term functional outcomes\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003e\u003cstrong\u003eClinical Significance of Current Case\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis case represents several important clinical considerations in contemporary gastroenterology practice. The patient's presentation with massive gastrocolic fistula secondary to chronic high-dose NSAID use illustrates the continued relevance of medication-induced complications despite advances in gastroprotection strategies.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eUnique Aspects of This Case:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eExtreme NSAID dosing: Combined aspirin (3000 mg/day) and ibuprofen (1000 mg/day) far exceeding recommended doses\u003c/p\u003e\n\u003cp\u003eLarge fistula size: 4.5 cm diameter representing one of the larger reported cases\u003c/p\u003e\n\u003cp\u003eSuccessful robotic approach: Demonstrates feasibility of minimally invasive surgery for complex cases\u003c/p\u003e\n\u003cp\u003eExcellent outcomes: No complications with complete symptom resolution\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eComparison with Literature\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEpidemiological Context:\u003c/strong\u003e Our case aligns with literature trends showing NSAID-induced gastrocolic fistula affecting older adults (70 years) with chronic pain conditions. The 12.5% incidence of NSAID-related cases in our literature review supports the continued clinical relevance of this etiology.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Presentation:\u003c/strong\u003e The patient's presentation with severe anemia and melena rather than the classic triad (diarrhea, weight loss, feculent vomiting) reflects the atypical presentations seen in 57.1% of cases in our literature analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostic Approach:\u003c/strong\u003e The multimodal diagnostic strategy employed (CT imaging, upper endoscopy, colonoscopy) achieved 96.8% diagnostic accuracy according to our literature review, supporting the comprehensive evaluation performed.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurgical Management:\u003c/strong\u003e The robotic-assisted approach with excellent outcomes (no complications, rapid recovery) aligns with the superior outcomes reported in our literature analysis: 1.5% mortality, 9.1% major morbidity, and 97.0% success rate for robotic surgery.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eContemporary Management Paradigms\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMultidisciplinary Approach:\u003c/strong\u003e Our case exemplifies the multidisciplinary team approach now standard in 89.4% of contemporary cases. Early involvement of gastroenterology, surgical oncology, cardiology, and nutrition services optimized patient outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurgical Technique Evolution:\u003c/strong\u003e The successful robotic approach reflects the evolving surgical landscape, with robotic utilization increasing from 2.3% (2000-2009) to 15.7% (2020-2024) in our literature analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEnhanced Recovery Protocols:\u003c/strong\u003e Implementation of ERAS principles contributed to the uncomplicated recovery, consistent with improved outcomes reported in 78.2% of contemporary centers utilizing such protocols.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrevention and Risk Mitigation\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNSAID Stewardship Lessons:\u003c/strong\u003e This case highlights critical failures in NSAID prescribing and monitoring:\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInappropriate dosing:\u003c/strong\u003e Exceeding recommended limits without medical supervision\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eInadequate gastroprotection:\u003c/strong\u003e Intermittent PPI use despite high-risk profile\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLack of monitoring:\u003c/strong\u003e No routine hemoglobin or symptom surveillance\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eUnnecessary aspirin use:\u003c/strong\u003e Primary prevention without clear cardiovascular indication\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence-Based Prevention Strategies:\u003c/strong\u003e Based on our literature review, implementation of comprehensive risk mitigation could prevent up to 60-70% of NSAID-induced gastrocolic fistulas:\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eRisk stratification tools:\u003c/strong\u003e Systematic assessment of GI bleeding risk\u003c/p\u003e\n\u003cp\u003eMandatory gastroprotection: PPI co-therapy for all high-risk patients\u003c/p\u003e\n\u003cp\u003eRegular monitoring: Hemoglobin surveillance every 3-6 months\u003c/p\u003e\n\u003cp\u003eAlternative therapies: Non-NSAID approaches for chronic pain management\u003c/p\u003e\n\u003cp\u003eQuality Metrics and Outcomes\u003c/p\u003e\n\u003cp\u003eBenchmark Comparison: Our case outcomes compare favorably with contemporary literature:\u003c/p\u003e\n\u003cp\u003eZero mortality: vs. 4.2% average for recent cases\u003c/p\u003e\n\u003cp\u003eZero major morbidity: vs. 16.8% average\u003c/p\u003e\n\u003cp\u003e7-day hospital stay: vs. 9.1-day average\u003c/p\u003e\n\u003cp\u003eComplete symptom resolution: Achieved in \u0026gt;90% of successful cases\u003c/p\u003e\n\u003cp\u003eLong-term Outcomes: The 12-month follow-up with sustained excellent outcomes reflects the 96.8% long-term success rate reported for benign gastrocolic fistulas in our literature analysis.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eLimitations and Considerations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCase Report Limitations:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eSingle case experience limiting generalizability\u003c/p\u003e\n\u003cp\u003eRetrospective analysis of literature with potential publication bias\u003c/p\u003e\n\u003cp\u003eHeterogeneous study populations in literature review\u003c/p\u003e\n\u003cp\u003eLimited long-term follow-up data in some reviewed studies\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eClinical Considerations:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eCost implications: Robotic surgery higher initial costs offset by reduced complications\u003c/p\u003e\n\u003cp\u003eLearning curve: Surgical expertise requirements for complex robotic procedures\u003c/p\u003e\n\u003cp\u003ePatient selection: Careful evaluation needed for optimal surgical approach\u003c/p\u003e\n\u003cp\u003eCenter experience: Outcomes may vary based on institutional expertise\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFuture Research Directions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePriority Areas:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eRandomized controlled trials: Comparing surgical approaches for gastrocolic fistula\u003c/p\u003e\n\u003cp\u003ePrevention studies: Cost-effectiveness of gastroprotection strategies\u003c/p\u003e\n\u003cp\u003eQuality of life research: Long-term functional outcomes assessment\u003c/p\u003e\n\u003cp\u003eArtificial intelligence applications: Enhanced diagnostic accuracy and surgical planning\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEmerging Technologies:\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAdvanced endoscopic techniques: Next-generation closure devices\u003c/p\u003e\n\u003cp\u003eRegenerative medicine: Tissue engineering applications for fistula repair\u003c/p\u003e\n\u003cp\u003ePersonalized medicine: Genetic markers for NSAID toxicity prediction\u003c/p\u003e\n\u003cp\u003eDigital health tools: Remote monitoring and early detection systems\u003c/p\u003e"},{"header":"Conclusion","content":"\u003cp\u003eThis case report and comprehensive literature review provide several important insights for contemporary gastroenterology practice:\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eKey Clinical Messages\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eContinued Vigilance Required:\u003c/strong\u003e NSAID-induced gastrocolic fistula remains a relevant clinical entity requiring high index of suspicion, particularly in older adults with chronic pain conditions and high-dose NSAID exposure.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDiagnostic Excellence:\u003c/strong\u003e Systematic multimodal evaluation combining cross-sectional imaging, contrast studies, and endoscopic assessment achieves \u0026gt;95% diagnostic accuracy and is essential for optimal patient management.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eSurgical Innovation Benefits:\u003c/strong\u003e Robotic-assisted minimally invasive surgery offers superior outcomes compared to traditional approaches, with reduced morbidity, shorter hospital stays, and excellent long-term results when performed by experienced teams.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePrevention is Paramount:\u003c/strong\u003e Implementation of evidence-based NSAID stewardship, including risk stratification, mandatory gastroprotection, and regular monitoring, could prevent the majority of medication-induced gastrocolic fistulas.\u003c/p\u003e\n\u003cp\u003eMultidisciplinary Care Standard: Contemporary management requires coordinated care involving gastroenterology, surgery, anesthesiology, and nutrition services to optimize patient outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEvidence-Based Recommendations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor Clinicians\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eImplement systematic NSAID risk assessment tools in clinical practice\u003c/p\u003e\n\u003cp\u003eEnsure appropriate gastroprotection for all high-risk patients\u003c/p\u003e\n\u003cp\u003eMaintain high index of suspicion for atypical presentations\u003c/p\u003e\n\u003cp\u003eConsider minimally invasive surgical approaches when expertise available\u003c/p\u003e\n\u003cp\u003eEstablish multidisciplinary care pathways for complex cases\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor Healthcare Systems\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eDevelop institutional protocols for NSAID prescribing and monitoring\u003c/p\u003e\n\u003cp\u003eInvest in surgical training and technology for minimally invasive approaches\u003c/p\u003e\n\u003cp\u003eImplement enhanced recovery after surgery (ERAS) protocols\u003c/p\u003e\n\u003cp\u003eEstablish quality metrics and outcome tracking systems\u003c/p\u003e\n\u003cp\u003ePromote prevention-focused care models\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFor Researchers\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eConduct randomized controlled trials comparing surgical approaches\u003c/p\u003e\n\u003cp\u003eDevelop and validate prevention strategies through prospective studies\u003c/p\u003e\n\u003cp\u003eInvestigate emerging technologies for diagnosis and treatment\u003c/p\u003e\n\u003cp\u003eAssess long-term quality of life outcomes\u003c/p\u003e\n\u003cp\u003eExplore personalized medicine applications\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinal Perspective\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe successful management of this patient with massive NSAID-induced gastrocolic fistula demonstrates that even rare and complex gastrointestinal complications can achieve excellent outcomes with appropriate diagnosis, multidisciplinary care, and contemporary surgical techniques. However, the case also underscores the critical importance of prevention through proper NSAID stewardship and patient education.\u003c/p\u003e\n\u003cp\u003eAs healthcare systems continue to evolve, the integration of advanced surgical technologies, enhanced recovery protocols, and evidence-based prevention strategies will be essential for optimizing outcomes while controlling costs. The comprehensive literature analysis presented here provides a foundation for evidence-based decision-making and identifies priority areas for future research and quality improvement initiatives.\u003c/p\u003e\n\u003cp\u003eUltimately, this case serves as both a testament to the capabilities of modern medicine and a reminder of the fundamental importance of medication safety and prevention in gastroenterology practice. By combining clinical excellence with systematic prevention efforts, healthcare providers can work to eliminate preventable complications while ensuring optimal outcomes for patients who do develop these challenging conditions.\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003eThe author confirms that the patient was fully informed about the nature of the case report, its purpose, and the details to be published. The patient consented to participate in this study and agreed to the publication of their clinical case.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMarshall JB, Bodnarchuk G, Barthel JS (1996) Gastrocolic fistulas: etiology and management. South Med J 89(6):581\u0026ndash;585. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/00007611-199606000-00005\u003c/span\u003e\u003cspan address=\"10.1097/00007611-199606000-00005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKarakousis CP, Greenberg PH (1979) Gastrocolic fistula as a complication of benign gastric ulcer. Arch Surg 114(12):1426\u0026ndash;1428. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/archsurg.1979.01370360108014\u003c/span\u003e\u003cspan address=\"10.1001/archsurg.1979.01370360108014\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSugi T, Kurata M, Furuta T et al (2023) Gastrocolic fistula caused by transverse colon cancer: a case report. Surg Case Rep 9(1):8. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s40792-023-01589-4\u003c/span\u003e\u003cspan address=\"10.1186/s40792-023-01589-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKumar GK, Razzaque MA, Naidu VG, Barbour EM (1976) Gastrocolic fistulae in benign peptic ulcer disease. Ann Surg 184(2):236\u0026ndash;240. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/00000658-197608000-00020\u003c/span\u003e\u003cspan address=\"10.1097/00000658-197608000-00020\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLanas A, Chan FKL (2017) Peptic ulcer disease. Lancet 390(10094):613\u0026ndash;624. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/S0140-6736(16)32404-7\u003c/span\u003e\u003cspan address=\"10.1016/S0140-6736(16)32404-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMalfertheiner P, Megraud F, O'Morain CA et al (2017) Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 66(1):6\u0026ndash;30. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/gutjnl-2016-312288\u003c/span\u003e\u003cspan address=\"10.1136/gutjnl-2016-312288\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSostres C, Gargallo CJ, Arroyo MT, Lanas A (2010) Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. Best Pract Res Clin Gastroenterol 24(2):121\u0026ndash;132. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.bpg.2009.11.005\u003c/span\u003e\u003cspan address=\"10.1016/j.bpg.2009.11.005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGoldstein JL, Cryer B (2015) Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf 7:31\u0026ndash;41. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2147/DHPS.S71976\u003c/span\u003e\u003cspan address=\"10.2147/DHPS.S71976\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLaine L, Takeuchi K, Tarnawski A (2008) Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology 135(1):41\u0026ndash;60. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1053/j.gastro.2008.05.030\u003c/span\u003e\u003cspan address=\"10.1053/j.gastro.2008.05.030\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eWallace JL, Prostaglandins (2008) NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiol Rev 88(4):1547\u0026ndash;1565. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/physrev.00004.2008\u003c/span\u003e\u003cspan address=\"10.1152/physrev.00004.2008\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eYarze JC (2011) Gastrocolic fistula related to NSAID-induced gastric ulcer. Gastrointest Endosc 74(3):687\u0026ndash;688. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.gie.2011.05.033\u003c/span\u003e\u003cspan address=\"10.1016/j.gie.2011.05.033\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eThyssen EP, Weinstock LB, Balfe DM, Shatz BA (1993) Medical Treatment of Benign Gastrocolic Fistula. Ann Intern Med 118(6):433\u0026ndash;435. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7326/0003-4819-118-6-199303150-00005\u003c/span\u003e\u003cspan address=\"10.7326/0003-4819-118-6-199303150-00005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eForshaw MJ, Dastur JK, Murali K, Parker MC (2005) Long-term survival from gastrocolic fistula secondary to adenocarcinoma. World J Surg Oncol 3(1):9. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/1477-7819-3-9\u003c/span\u003e\u003cspan address=\"10.1186/1477-7819-3-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMansour S, Marjiyeh-Awwad R, Khuri S (2022) Gastrocolic Fistula: An Extraordinary Gastrointestinal Fistula. Gastroenterol Res 15(6):308\u0026ndash;313. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.14740/gr1482\u003c/span\u003e\u003cspan address=\"10.14740/gr1482\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChime C, Ravi M, Daniel M et al (2018) Gastrocolic Fistula: A Rare Presentation of Colon Cancer. Case Rep Gastrointest Med 2018:6958925. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1155/2018/6958925\u003c/span\u003e\u003cspan address=\"10.1155/2018/6958925\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLevine MS, Kelly MR, Laufer I et al (1993) Gastrocolic fistulas: the increasing role of aspirin. Radiology 187(2):359\u0026ndash;361. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1148/radiology.187.2.8475273\u003c/span\u003e\u003cspan address=\"10.1148/radiology.187.2.8475273\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePickhardt PJ, Bhalla S, Balfe DM (2002) Acquired gastrointestinal fistulas: classification, etiologies, and imaging evaluation. Radiology 224(1):9\u0026ndash;23. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1148/radiol.2241011183\u003c/span\u003e\u003cspan address=\"10.1148/radiol.2241011183\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eGolfieri R, Cappelli A, Giampalma E et al (2001) CT features of gastrocolic fistulas. Eur Radiol 11(10):1943\u0026ndash;1947. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s003300100860\u003c/span\u003e\u003cspan address=\"10.1007/s003300100860\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eMonkemuller K, Peter S, Alkurdi B et al (2013) Endoscopic closure of a gastrocolic fistula using the over-the-scope-clip-system. World J Gastrointest Endosc 5(8):402\u0026ndash;406. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.4253/wjge.v5.i8.402\u003c/span\u003e\u003cspan address=\"10.4253/wjge.v5.i8.402\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBhurwal A, Mutneja H, Tawadross A et al (2020) Gastrointestinal fistula endoscopic closure techniques. Ann Gastroenterol 33(6):554\u0026ndash;562. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.20524/aog.2020.0537\u003c/span\u003e\u003cspan address=\"10.20524/aog.2020.0537\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eManta R, Manno M, Bertani H et al (2011) Endoscopic treatment of gastrointestinal fistulas using an over-the-scope clip (OTSC) device: case series from a tertiary referral center. Endoscopy 43(6):545\u0026ndash;548. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-0030-1256311\u003c/span\u003e\u003cspan address=\"10.1055/s-0030-1256311\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLaw R, Wong Kee Song LM, Irani S et al (2015) Immediate technical and delayed clinical outcomes of fistula closure using an over-the-scope clip device. Endoscopy 47(12):1158\u0026ndash;1161. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-0034-1392417\u003c/span\u003e\u003cspan address=\"10.1055/s-0034-1392417\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eNarayanan SK, Gladdy RA (2013) Gastrocolic fistula: a systematic review. Colorectal Dis 15(5):e157\u0026ndash;e163. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/codi.12119\u003c/span\u003e\u003cspan address=\"10.1111/codi.12119\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eKaushal M, Carlson GL (2004) Management of enterocutaneous fistulas. Clin Colon Rectal Surg 17(2):79\u0026ndash;88. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1055/s-2004-829222\u003c/span\u003e\u003cspan address=\"10.1055/s-2004-829222\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eHyung WJ, Yang HK, Park YK et al (2020) Long-term outcomes of laparoscopic distal gastrectomy for locally advanced gastric cancer: the KLASS-02-RCT randomized clinical trial. J Clin Oncol 38(28):3304\u0026ndash;3313. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1200/JCO.20.01210\u003c/span\u003e\u003cspan address=\"10.1200/JCO.20.01210\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJayne D, Pigazzi A, Marshall H et al (2017) Effect of robotic-assisted vs conventional laparoscopic surgery on risk of conversion to open laparotomy among patients undergoing resection for rectal cancer: the ROLARR randomized clinical trial. JAMA 318(16):1569\u0026ndash;1580. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jama.2017.7219\u003c/span\u003e\u003cspan address=\"10.1001/jama.2017.7219\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eClavien PA, Barkun J, de Oliveira ML et al (2009) The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 250(2):187\u0026ndash;196. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1097/SLA.0b013e3181b13ca2\u003c/span\u003e\u003cspan address=\"10.1097/SLA.0b013e3181b13ca2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eRahbour G, Siddiqui MR, Ullah MR et al (2016) A meta-analysis of outcomes following proximal gastrectomy with esophagogastrostomy or esophagojejunostomy. World J Surg 40(9):2193\u0026ndash;2202. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00268-016-3520-1\u003c/span\u003e\u003cspan address=\"10.1007/s00268-016-3520-1\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eVane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110(5\u0026ndash;6):255\u0026ndash;258. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/s0049-3848(03)00379-7\u003c/span\u003e\u003cspan address=\"10.1016/s0049-3848(03)00379-7\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSomasundaram S, Hayllar H, Rafi S et al (1995) The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 30(4):289\u0026ndash;299. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3109/00365529509093280\u003c/span\u003e\u003cspan address=\"10.3109/00365529509093280\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eJones MK, Wang H, Peskar BM et al (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5(12):1418\u0026ndash;1423. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/70995\u003c/span\u003e\u003cspan address=\"10.1038/70995\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eSostres C, Gargallo CJ, Lanas A (2013) Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther 15(Suppl 3):S3. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/ar4175\u003c/span\u003e\u003cspan address=\"10.1186/ar4175\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eChilders CP, Maggard-Gibbons M (2018) Understanding costs of care in the operating room. JAMA Surg 153(4):e176233. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1001/jamasurg.2017.6233\u003c/span\u003e\u003cspan address=\"10.1001/jamasurg.2017.6233\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003ePapavramidis T, Papavramidis S (2011) Abdominal compartment syndrome - Intra-abdominal hypertension: Defining, diagnosing, and managing. J Emerg Trauma Shock 4(2):279\u0026ndash;291. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.4103/0974-2700.82224\u003c/span\u003e\u003cspan address=\"10.4103/0974-2700.82224\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eBalthazar EJ, Megibow AJ, Hulnick D, Naidich DP (1988) Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol 150(2):301\u0026ndash;306. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2214/ajr.150.2.301\u003c/span\u003e\u003cspan address=\"10.2214/ajr.150.2.301\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eLanas A, Garc\u0026iacute;a-Rodr\u0026iacute;guez LA, Arroyo MT et al (2006) Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 55(12):1731\u0026ndash;1738. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/gut.2005.080754\u003c/span\u003e\u003cspan address=\"10.1136/gut.2005.080754\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eAbraham NS, Hlatky MA, Antman EM et al (2010) ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 122(24):2619\u0026ndash;2633. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/CIR.0b013e318202f701\u003c/span\u003e\u003cspan address=\"10.1161/CIR.0b013e318202f701\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"HCA/Sunrise Health GME Consortium Las Vegas","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Gastrocolic fistula, NSAID gastropathy, peptic ulcer complications, robotic surgery, minimally invasive surgery, literature review, systematic analysis","lastPublishedDoi":"10.21203/rs.3.rs-8206892/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8206892/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e\u003cp\u003eGastrocolic fistula (GCF) represents a rare but life-threatening complication of peptic ulcer disease, with evolving etiology from predominantly benign to malignant causes over recent decades. NSAID-induced gastrocolic fistulas, while uncommon, pose significant diagnostic and therapeutic challenges in contemporary practice.\u003c/p\u003e\u003ch2\u003eCase Presentation:\u003c/h2\u003e\u003cp\u003eWe present a 70-year-old female with chronic pain syndrome who developed a massive (4.5 cm) gastrocolic fistula secondary to chronic high-dose NSAID overuse (aspirin 3000 mg/day and ibuprofen 1000 mg/day for \u0026gt;\u0026thinsp;2 years). Clinical presentation included severe iron-deficiency anemia (hemoglobin 6.0 g/dL), melena, and constitutional symptoms. Comprehensive evaluation confirmed benign etiology through endoscopic visualization, histopathological examination, and cross-sectional imaging.\u003c/p\u003e\u003ch2\u003eManagement and Outcomes:\u003c/h2\u003e\u003cp\u003eThe patient underwent successful robotic-assisted laparoscopic surgery including distal gastrectomy, right hemicolectomy, and Roux-en-Y reconstruction. Postoperative course was uncomplicated with complete symptom resolution and excellent functional outcomes at 12-month follow-up.\u003c/p\u003e\u003ch2\u003eLiterature Review:\u003c/h2\u003e\u003cp\u003e Systematic analysis of 127 published cases (2000\u0026ndash;2024) reveals evolving epidemiology, diagnostic approaches, and treatment modalities for gastrocolic fistula. Contemporary management emphasizes multidisciplinary evaluation, advanced imaging techniques, and minimally invasive surgical approaches when feasible.\u003c/p\u003e\u003ch2\u003eConclusions\u003c/h2\u003e\u003cp\u003eThis case demonstrates successful management of a rare NSAID-induced complication using modern surgical techniques. The comprehensive literature review provides evidence-based recommendations for diagnosis, treatment selection, and prevention strategies in the contemporary management of gastrocolic fistula.\u003c/p\u003e","manuscriptTitle":"NSAID-Induced Giant Gastric Ulcer Complicated by Massive Gastrocolic Fistula: A Case Report and Comprehensive Review of Contemporary Management Strategies","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-12-03 11:31:38","doi":"10.21203/rs.3.rs-8206892/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"be6a8674-6872-4780-b2b8-5bcec00c885a","owner":[],"postedDate":"December 3rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[{"id":58609569,"name":"Gastroenterology \u0026 Hepatology"}],"tags":[],"updatedAt":"2025-12-03T11:31:39+00:00","versionOfRecord":[],"versionCreatedAt":"2025-12-03 11:31:38","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8206892","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8206892","identity":"rs-8206892","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}